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Abstract
Background: Studies of the genetic basis of drug response could help clarify mechanisms of drug action/metabolism, and
facilitate development of genotype-based predictive tests of efficacy or toxicity (pharmacogenetics).
Objectives: We conducted a systematic review and field synopsis of pharmacogenetic studies to quantify the scope and
quality of available evidence in this field in order to inform future research.
Data Sources: Original research articles were identified in Medline, reference lists from 24 meta-analyses/systematic
reviews/review articles and U.S. Food and Drug Administration website of approved pharmacogenetic tests.
Study Eligibility Criteria, Participants, and Intervention Criteria: We included any study in which either intended
or adverse response to drug therapy was examined in relation to genetic variation in the germline or cancer cells in
humans.
Study Appraisal and Synthesis Methods: Study characteristics and data reported in abstracts were recorded. We further
analysed full text from a random 10% subset of articles spanning the different subclasses of study.
Results: From 102,264 Medline hits and 1,641 articles from other sources, we identified 1,668 primary research articles (1987
to 2007, inclusive). A high proportion of remaining articles were reviews/commentaries (ratio of reviews to primary research
approximately 25:1). The majority of studies (81.8%) were set in Europe and North America focussing on cancer,
cardiovascular disease and neurology/psychiatry. There was predominantly a candidate gene approach using common
alleles, which despite small sample sizes (median 93 [IQR 40–222]) with no trend to an increase over time, generated a high
proportion (74.5%) of nominally significant (p,0.05) reported associations suggesting the possibility of significance-chasing
bias. Despite 136 examples of gene/drug interventions being the subject of $4 studies, only 31 meta-analyses were
identified. The majority (69.4%) of end-points were continuous and likely surrogate rather than hard (binary) clinical
end-points.
Conclusions and Implications of Key Findings: The high expectation but limited translation of pharmacogenetic research
thus far may be explained by the preponderance of reviews over primary research, small sample sizes, a mainly candidate
gene approach, surrogate markers, an excess of nominally positive to truly positive associations and paucity of meta-
analyses. Recommendations based on these findings should inform future study design to help realise the goal of
personalised medicines.
Systematic Review Registration Number: Not Registered
Citation: Holmes MV, Shah T, Vickery C, Smeeth L, Hingorani AD, et al. (2009) Fulfilling the Promise of Personalized Medicine? Systematic Review and Field
Synopsis of Pharmacogenetic Studies. PLoS ONE 4(12): e7960. doi:10.1371/journal.pone.0007960
Editor: Yuan Luo, University of Maryland School of Pharmacy, United States of America
Received July 31, 2009; Accepted October 23, 2009; Published December 2, 2009
Copyright:  2009 Holmes et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The work reported was not the subject of a specific research grant. Aroon D. Hingorani is funded by a Senior Research Fellowship from the British Heart
Foundation (FS 05/125). Liam Smeeth is funded by a Wellcome Trust Senior Research Fellowship in Clinical Science (082178). Michael V. Holmes is fundedb ya n
Academic Clinical Fellowship from the National Institute for Health Research and a Population Health Scientist Fellowship from the Medical Research Council
(G0802432). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: Aroon Hingorani is on the Editorial Board of the Drug and Therapeutics Bulletin (International Society of Drug Bulletins). He has received
honoraria for speaking at educational meetings with a pharmaceutical sponsor but has donated these in whole or part to various medical charities. He has acted
as a consultant to London Genetics and to GSK.
* E-mail: a.hingorani@ucl.ac.uk (ADH); Juan.Pablo-Casas@lshtm.ac.uk (JPC)
. These authors contributed equally to this work.
PLoS ONE | www.plosone.org 1 December 2009 | Volume 4 | Issue 12 | e7960Introduction
Individual differences in drug efficacy, or susceptibility to adverse
effects, collectively make an important contribution to the burden of
ill-health [1,2]. Studying the genetic basis could reduce this by
clarifying pathways and mechanisms of drug action or metabolism
to inform drug development, and by the development of genotype-
based predictive tests of efficacy or toxicity (pharmacogenetics).
As with research in common disease susceptibility, the path to
translation involves a two stage process that first requires the
reliable identification of the genetic loci involved, and then
research into the healthcare applications of this knowledge, which
includes critical appraisal of the performance of genotype as a
predictive test. While the extent of the clinical impact of research
in both areas is uncertain, the reliable identification of loci
involved in drug response (pharmacogenetics) appears to be less
advanced than the identification of susceptibility loci for common
disease [3]. After more than two decades of research, a continuing
expansion in the range and depth of available drug therapies, and
the continued promise of ‘personalized medicine,’[4,5,6,7,8,9]
only four pharmacogenetic tests were mandated as part of the
FDA drug approval pre-July 2009, [10] while for another 10 tests
recommended by the FDA, clinical utility is not universally agreed
[11,12,13]. Understanding the reasons for the blocks in develop-
ment of personalised medicines could help improve efficiency of
future research.
Systematic reviews and field synopses previously exposed the
obstacles to progress in complex disease genetics. These included:
a focus on candidate genes rather than genome-wide analysis;
inadequate sample size; suboptimal capture of genetic variation;
and significance chasing and reporting bias; all of which led to a
failure to replicate and validate genetic associations [14,15,16].
These overviews [17,18,19] were followed by improvements in
research design which made an important contribution to the
recent success in the identification in genes for common disease
[20]. These considerations and the absence of a prior systematic,
quantitative overview of pharmacogenetic research was the
motivation for the current study.
Methods
We followed PRISMA 2009 guidelines [21].
Search Strategy
We identified pharmacogenetic studies using a carefully designed
search strategy. We searched articles indexed in Medline using the
Medical Subject Heading (MeSH) or full text terms (‘‘Genetic
Variation’’[MeSH] or ‘‘Genotype’’[MeSH] or ‘‘Genes’’[MeSH] or
genotype* or polymorphism* or allele* or mutation*) and (‘‘Treat-
ment Outcome’’[MeSH] or ‘‘Therapeutics’’[MeSH] or ‘‘adverse
effects’’[Subheading] or ‘‘Pharmacogenetics’’[MeSH] or ‘‘Toxico-
genetics’’[MeSH] or pharmacogenomic* or pharmacogenetic* or
toxicogenetic* or therapeutic* or intervention* or treatment*) from
inception up to 01-01-2008. The search was initially restricted to
Human studies and subsequently to Clinical Trials, Meta-Analyses,
Practice Guidelines, and Randomized Controlled Trials using the
Medline filters and by doing so excluded Editorials, Reviews and
Letters. We supplemented the search with relevant references
indexed in 12 meta-analyses and 12 review articles (spanning most
disease categories). The FDA ‘‘Table of Valid Genomic Biomarkers
in the Context of Approved Drug Labels’’[10] was also cross-
referenced and to identify potentially missing meta-analyses, the
ten most frequently studied genes in each category (germ-line
[kinetic/dynamic] and somatic) were individually searched in
Medline (none extra was found). Furthermore, as some meta-
analyses are indexed in Medline as reviews and thus had the
potential to be excluded during the initial search, we repeated our
Medline search selecting only meta-analyses.
To be eligible for inclusion, studies had to satisfy our definition of
a pharmacogenetic study: a study in which the response (intended
outcome/adverse reaction) to drug therapy was examined in
relation to genetic variation (germline/somatic) in humans. It was
mandatory that participants be genotyped (studies using phenotype
asa surrogate ofgenetic variationwereexcluded)andthat .1allelic
variations at a gene were analysed (in order to compare differing
alleles on response to treatment). All abstracts from the Medline
search were screened to determine if they fulfilled the inclusion
criteria by MH, aided by CV. Two authors blindly assessed a
random subset of abstracts to corroborate inclusion and exclusion
(JPC, AH). One hundred and sixty-one articles were chosen at
random (,16 papers/year from 1998–2007 inclusive) and full texts
were scrutinized in more detail.
Data Extraction
The following were extracted and recorded from the abstracts of
included articles: year of publication; first author; journal name;
continent of correspondence; language of publication; disease
category; study design; gene(s) studied and whether variation was
in somatic (cancer) cells or in the germline and, if germline,
whether related to drug absorption/distribution/metabolism/
elimination (pharmacokinetic) or the drug target (pharmacody-
namic) and whether the study was primarily set up to investigate
the pharmacogenetic end-point. We also extracted information on:
the primary outcome including whether this was the intended or
an adverse effect of the drug; the number and magnitude of
reported p values in each study (categorized as only non-significant
p values [p.0.05], only significant p values [p#0.05] and mixed
[p values both # and .0.05]); specific drugs, further classified
according to the British National Formulary coding (http://www.
bnf.org accessed 2009 November 10, archived URL http://www.
webcitation.org/5lBYIOLVR) and the 2006 impact factor of
the publication (derived from Journal Citation Reports H ISI Web
of Knowledge
SM (http://www.isiwebofknowledge.com accessed
2009 November 10, archived URL http://www.webcitation.org/
5lBTT863z) grouped into 0 to 4.99, 5–9.99 and $10. From the
161 full-text articles, data were also extracted on: (i) genes and
alleles investigated, including the mean allele frequency (MAF); (ii)
outcomes, classified according to their clinical end-point into
binary and continuous; (iii) the number of analyses and p values
reported from gene-drug interactions.
Definition of Disease Category
Disease categories were organ-specific with the exception of (i)
cancer, which encompassed any body site in which there was
neoplasia, and (ii) anti-coagulation, classified as ‘cardiovascular’.
The cardiovascular disease category also included acute myocar-
dial infarction and peripheral vascular disease; neurology/
psychiatry included stroke, psychosis, and depression; endocrine
disease included diabetes and hyperlipidaemia (where the outcome
assessed was a change in lipid level and not the effect on
cardiovascular end-points).
Gene Nomenclature and Classification
Genes were named according to HUGO (HUman Genome
Organisation) Gene Nomenclature Committee (HGNC, Wellcome
Trust; http://www.genenames.org accessed 2009 November 10,
archived URL http://www.webcitation.org/5lBCXvH6E). The
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the Pharmacogenomics Knowledge database (PharmGKB; http://
www.pharmgkb.org accessed 2009 November 10, archived URL
http://www.webcitation.org/5lBChBcLk). Where it was not possi-
ble to precisely classify the specific gene according to HUGO
nomenclature, an asterisk was placed after the initial characters (e.g.
HTR* denotes serotonin receptor genes, of which HTR1B and
HTR2A are specific examples).
Outcomes Recorded
A study in which the outcome investigated was the desired effect
of the drug (e.g. pH lowering from use of a proton pump inhibitor)
was defined as ‘intended effect’; one in which the outcome was
adverse was classified as an ‘adverse effect’ (this encompassed both
hypersensitivity and dose-dependent adverse reactions).
For the 161 full-text papers, outcomes were classified as binary
or continuous: examples of binary were death, disease recurrence,
or an episode of bleeding; examples of continuous were changes in
the plasma levels of a drug, gastric pH or international normalised
ratio (INR, e.g. for the monitoring of warfarin anticoagulation).
Continent of Correspondence
The continent of correspondence was determined from the
Medline citation and used as a surrogate marker for the geographic
location of the study.
Study Design
The study design was categorized as: (i) prospective (including
randomized clinical trials), (ii) case-control, (iii) cross-sectional, or
(iv) meta-analysis.
Primary/Secondary Pharmacogenetic Study
A primary pharmacogenetic study was defined as one in which
the title of the study or the stated aims or purpose within the text of
the abstract indicated that the primary intention of the study was
to investigate the effect of genetic variation on drug response. If
not explicitly stated, the study was classified as a secondary
pharmacogenetic study.
Exclusions
We excluded the following as ‘drug’ treatments: ionizing
radiation, surgical procedures, non-drug-eluting stents, bone
marrow transplantation, tobacco, alcohol, environmental agents
or pollutants (e.g. lead), herbal remedies, dietary or lifestyle
interventions including acupuncture, massage, counseling, or
exercise.
U.S. Food and Drug Administration (FDA) Guidelines
We analysed the evidence-base behind the FDA list of approved
pharmacogenetic tests (pre-July 2009) [10]. The articles cited in
support of FDA labeling as ‘test required’ or ‘test recommended’
were reviewed (Document S1). Tests (gene and drug pairs) were
cross-referenced with the generated database. FDA recommenda-
tions were contrasted with guidelines from authoritative medical
bodies.
Statistical Analysis
Statistical analyses were performed using SPSS for Windows
version 17.0 and Stata 10. A value of p#0.001 was taken as
significant. Frequency distributions were analysed for normality by
2-tailed Chi-Square. Impact factors were ranked by Mann-
Whitney U. Sample sizes were converted into logarithmic (loge)
values and means compared with unpaired student’s t.
Results
Articles Retrieved
A sensitive, non-specific search strategy in Medline (see
Methods) yielded 102,264 articles (Figure 1) with an additional
1,641 articles identified from other sources. 97,339 (94%) articles
were annotated as reviews, editorials or letters rather than primary
research, and were excluded. Of the 6,548 remaining articles, a
total of 1,668 (1.6% of studies from the initial search) reported
original research that fulfilled all our inclusion criteria. A much less
sensitive search strategy utilising the MeSH term ‘‘pharmacoge-
netics’’ retrieved only 4674 articles, of which 183 (4%) were
indexed as original research (Figure 2).
Characteristics of Pharmacogenetic Studies
We noted a marked increase in the number of primary
pharmacogenetic research studies (and other types of article) since
1990 (Figure 2). The majority of articles reporting original
research investigated variation in the germline (1327, 79.6%,
Table 1) and of these, the greater proportion studied genetic
variation in drug targets (pharmacodynamic studies; 804, 60.6%)
rather than genes encoding proteins involved in drug handling and
elimination (pharmacokinetic). Most pharmacogenetic studies
were prospective in design (1496, 89.7%) with about one-half
(852; 51.1%) set in Europe or Australasia and one-third in North
America (511 studies; 30.7%). The most frequently investigated
disease areas were cancer (456 studies; 27.3%), neurology/
psychiatry (321 studies; 19.2%) and cardiovascular disease (287
studies; 17.2%) with a relative paucity of studies in infectious
disease (106 studies, 6.4%) and respiratory medicine (49 studies,
2.9%). Most studies evaluated the intended effects of the drug
under investigation (1190 studies; 71.6%); only one-eighth of
studies (210, 12.6%) examined adverse drug effects, with
pharmacokinetic rather than pharmacodynamic studies being
more likely to do so (p=2.02610
214).
Genes Investigated and Number of Participants
The breadth of work and the foci of activity are illustrated by
the total number of genes in each category and those most
frequently studied (Figure 3). There were in total 541 genes studied
(176 somatic, 305 pharmacodynamic and 70 pharmacokinetic
with some overlap for 10 genes). Seven genes included studies
involving over 10,000 participants in aggregate: two somatic (TP53
and non-specified karyotype mutations), 2 pharmacokinetic
(MTHFR and CYP2C9) and 3 pharmacodynamic genes (ACE,
AGT and APOE). About one-third (37.7%) of study participants
were distributed among the 10 most frequently studied somatic
genes; with the equivalent numbers in kinetic and dynamic studies
being 68.5% and 41.8%, respectively. Thirteen of 70 (18.6%)
kinetic genes, 22 of 305 (7.2%) dynamic genes and 12 of 176
(6.8%) somatic genes included more than 10 studies.
Most Frequently Studied Gene-Drug Combinations
The 10 most studied cancer cell gene variants were TP53 and
cisplatin/5-fluorouracil/paclitaxel response, ERBB2 (HER2/neu)
and anthracyclines/trastuzumab response, EGFR and gefitinib
response, and RAS, FLT3, ABCB1, BCL2 and t(9;22) and other
karyotype and cytogenetic mutations and response to a variety of
combination chemotherapy regimens. The most studied germline
pharmacokinetic and pharmacodynamic genes (Figure 4) were
ACE and cardiovascular drug response (n=79), CYP2D6 and
response to antidepressant therapy (n=74), CYP2C19 and
response to gastrointestinal drugs (mostly proton pump inhibitors,
n=52), MTHFR and response to nutritional drugs (predominantly
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(n=34), CYP2C9 and cardiovascular drugs (mainly warfarin,
n=33), APOE and response to drugs targeting the cardiovascular
(n=29) and central nervous system (CNS, n=31), TPMT and
response to chemotherapy/immunosuppression (mostly azathio-
prine, n=29), and HTR* (n=27) and DRD2 (n=27) and response
to CNS drugs. However with the exception of ERBB2(HER2/
neu)/trastuzumab therapy, CYP2C9/warfarin and TPMT/azathi-
oprine none of these genes are mandated or recommended by the
FDA for pharmacogenetic testing [10].
Figure 1. Flow chart of methodology for identifying pharmacogenetic studies in the systematic review. From PRISMA 2009
guidelines [21].
doi:10.1371/journal.pone.0007960.g001
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We next focused on indices of clinical relevance and study
quality. As in clinical trials, continuous outcome measures in
pharmacogenetic studies are more likely to be surrogates for more
clinically relevant binary outcomes. For example, the international
normalized ratio (INR), an index of the anticoagulant effect of
warfarin, might be used as a surrogate for the risk of a major
hemorrhage, a serious adverse clinical event arising from warfarin
treatment. From the representative subset of 161 full-text articles,
continuous outcomes were more frequently reported than binary
outcomes. Of a total of 546 reported outcomes, less than one-third
(167, 30.6%) were binary, and these were more likely to be
reported in studies of genetic variation in cancer cells (median
binary outcomes/paper: 2, IQR 1–3.25) than germ-line studies
(median binary outcomes/paper: 0, IQR 0-1).
Sample Size
Sample size in genetic studies can serve as an index of the
quality and reliability because unless effect sizes are large, small
studies may be inadequately powered to detect plausible genetic
effects reliably [22,23,24]. Common alleles (those with a minor
allele frequency, MAF, .0.05) tend to exert smaller effects on
disease risk than rare alleles [25], with effect sizes for binary
outcomes in gene-disease association studies being odds ratios for
disease risk in the range of 1.28–1.65 [24]. Moreover, where a
positive effect is seen in a small study of common alleles, a false
positive association may be as or more likely than a true positive
[22,24]. In the representative subset of full text articles of
pharmacogenetic research, the median MAF of the variants
studied was 0.12 (IQR 0.08–0.67), suggesting that similar effect
sizes for binary outcomes might be expected in pharmacogenetic
studies; reliable detection of effect sizes in this range would require
sample sizes in the region of 3,500 [24]. However, the vast
majority of pharmacogenetic studies were far smaller (median
sample size 93) and the distribution highly skewed (IQR 40–222).
Moreover, there was little evidence for an increase in sample size
over time (Figure 5). Although pharmacodynamic studies (median
sample size 102, IQR 51–273) tended to be larger than
pharmacokinetic studies (median sample size 70, IQR 25-136,
p=7.61610
215) in neither case was the size of studies comparable
to recent candidate gene or genome wide disease association
studies [26]. Larger studies tended to achieve publication in higher
than intermediate or lower impact journals (p=2.99610
27) and
articles from North America, Europe & Australasia had larger
sample sizes than those from Asia (p=2.21610
26). However, most
articles were published in journals of modest impact factor (median
Figure 2. Growth in publications in the field of pharmacogenetics from 1967–2007 (inclusive). Our detailed search strategy incorporating
both Medical Subject Headings (MeSH) and free-text terms (filtered for Humans and excluding Reviews/Editorials) identified 6,548 original articles
(purple bars) of which 1,668 fulfilled the inclusion criteria (green bars). By contrast the total number of articles obtained based on a search using the
MeSH term ‘‘pharmacogenetics’’ (including reviews and editorials) was 4,674, of which only 183 were original articles (red bars), indicating a ratioo f
approximately 1:25 of original research to commentary/review.
doi:10.1371/journal.pone.0007960.g002
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factor ,5), with no clear trend for an emergence of a larger
proportion of high impact factor articles over time (p=0.861).
Impact factors were higher in studies of genetic variation in
cancer cells (p=2.07610
214) and articles from North America
(p=2.17610
213) compared to others in their respective groups.
Table 1. Characteristics of pharmacogenetic studies included in the systematic review.
All (n=1668{) Somatic (n=341) Dynamic (n=804) Kinetic (n=465) Full-text (n=161)
Sample size Median (IQR) { 93 (40–222) 90 (39–281) 102 (51–273) 70 (25–136) 95 (43–246)
Full-text articles 161 29 (18.0%) 80 (49.7%) 48 (29.8%)
Study Design,n o .( % )*
Prospective 1,496 (89.7%) 321 (94.1%) 716 (89.1%) 411 (88.6%) 146 (90.7%)
Case-control 92 (5.5%) 6 (1.8%) 55 (6.8%) 27 (5.8%) 9 (5.6%)
Cross-sectional 40 (2.4%) 2 (0.6%) 20 (2.5%) 13 (2.8%) 4 (2.5%)
Meta-analyses 32 (1.9%) 11 (3.2%) 10 (1.2%) 10 (2.2%) 1 (0.6%)
Unable 7 (0.4%) 1 (0.3%) 3 (0.4%) 3 (0.6%) 1 (0.6%)
Language, no. (%)
English 1,638 (98.2%) 339 (99.4%) 784 (97.5%) 458 (98.5%) 161
Other 30 (1.8%) 2 (0.6%) 20 (2.5%) 7 (1.5%) 0
Continent of correspondence,
no. (%)
Europe & Australasia 852 (51.1%) 160 (46.9%) 431 (53.7%) 234 (50.3%) 84 (52.2%)
N America 511 (30.7%) 145 (42.5%) 240 (29.9%) 105 (22.6%) 49 (30.4%)
Asia 242 (14.5%) 27 (7.9%) 96 (12.0%) 113 (24.3%) 25 (15.5%)
Other 55 (3.3%) 8 (2.3%) 31 (3.9%) 12 (2.6%) 3 (1.9%)
Not specified 7 (0.4%) 1 (0.3%) 5 (0.6%) 1 (0.2%) 0
Disease category,n o .( % )
Cancer 456 (27.3%) 341 (100%) 37 (4.6%) 68 (14.6%) 37 (23.0%)
Neurology/Psychiatry 321 (19.2%) 0 228 (28.4%) 81 (17.4%) 26 (16.1%)
Cardiovascular 287 (17.2%) 0 193 (24.0%) 76 (16.3%) 34 (21.1%)
Endocrine 164 (9.8%) 0 135 (16.8%) 25 (5.4%) 16 (9.9%)
Other 440 (26.4%) 0 211 (26.2%) 215 (46.2%) 48 (29.8%)
Pharmacogenetic design,n o .( % )
Primary 1,364 (81.8%) 249 (73.0%) 661 (82.2%) 403 (86.7%) 137 (85.1%)
Secondary 258 (15.5%) 77 (22.6%) 122 (15.2%) 54 (11.6%) 23 (14.3%)
Unable 46 (2.8%) 15 (4.4%) 21 (2.6%) 8 (1.7%) 1 (0.6%)
Outcome, no. (%)
Intended effect 1,190 (71.6%) 314 (92.4%) 634 (79.2%) 208 (44.8%) 115 (71.4%)
Adverse effect 210 (12.6%) 2 (0.6%) 116 (14.5%) 80 (17.2%) 19 (11.8%)
Both 99 (6.0%) 17 (5.0%) 26 (3.2%) 47 (10.1%) 7 (4.3%)
Other 164 (9.9%) 7 (2.1%) 25 (3.1%) 129 (27.8%) 1 20(12.4%)
Impact factor, no. (%)
0 to 4.99** 903 (54.1%) 141 (41.3%) 453 (56.3%) 275 (59.1%) 72 (44.7%)
5 to 9.99 507 (30.4%) 73 (21.4%) 256 (31.8%) 163 (35.1%) 59 (36.6%)
$10 258 (15.5%) 127 (37.2%) 95 (11.8%) 27 (5.8%) 30 (18.6%)
Pv a l u ec a t e g o r y , no. (%)H
Only p values,0.05 608 (74.5%) 120 (67.4%) 286 (75.7%) 177 (77.3%) 57 (70.4%)
Mixed p values 132 (16.2%) 37 (20.8%) 52 (13.8%) 40 (17.5%) 17 (21.0%)
Only p values.0.05 76 (9.3%) 21 (11.8%) 40 (10.6%) 12 (5.2%) 7 (8.6%)
{58 of 1,668 studies are mixed dynamic/kinetic.
{Meta-analyses excluded, values are for 1504 abstracts that report a sample size. 4 of 161 full-text articles were mixed pharmacokinetic/pharmacodynamic.
*Percentages are of total.
**Includes journal that are not listed with ISI.
HFor 816 abstracts reporting a p value or 81 full-text papers.
1Studies investigating plasma levels of drugs.
doi:10.1371/journal.pone.0007960.t001
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(n=305); (b) pharmacokinetic genes (n=70); and (c) somatic genes (n=176). * refers to .1 gene and/or non-HUGO nomenclature.
doi:10.1371/journal.pone.0007960.g003
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Significance chasing bias, evidenced by a disproportionate report-
ingofextremep valuesinsmall studies,previouslyaffected candidate
gene disease association studies [27]. To assess whether this might
also be the case in the pharmacogenetic literature, we evaluated the
distribution of reported p values in abstracts of primary research
articles. About one half of study abstracts (816, 48.9%) reported a p
value. Three quarters of these articles reported only significant p
values (608 abstracts, 74.5%). There was no difference (p=0.926) in
the sizeofstudiesamongthe three p value categories:median sample
size (IQR) of articles reporting only non-significant p values was 99
(57–292); mixed (significant and non-significant) p values was 103
(48–252); and only significant p values was 106 (49–252). These
findings were corroborated in the detailed analysis of 161 full papers
(p=0.608).
The predominance of significant p values suggests either that
the prior odds of success in pharmacogenetics is higher than in
most other fields of biomedical research, or that the published
literature is affected by chance findings and/or publication bias
[22]. Another index of significance chasing bias is the total number
of hypotheses tested by any study. One hundred and twenty five of
161 full-text articles reported a p value (Figure 6) with a median of
6 p values per article (IQR 3–12). These 161 articles had a
theoretical median of 12 total reportable comparisons per study
(IQR 4–29, Figure 7, calculated by number of alleles x number of
drugs x number of outcomes recorded), suggesting that the
potential for post-hoc subgroup analysis is large in pharmacoge-
netic research.
Use of Meta-Analysis
Meta-analysis has been used to strengthen conclusions regard-
ing genetic effects on disease outcomes [28,29,30]. Thirty one
meta-analyses of pharmacogenetic studies were identified span-
ning 29 genes (Table 2), 23 of which included 4 or more studies.
However, a further 107 genes that were the subject of $4 studies
had never been the subject of a meta-analysis. The majority of
meta-analyses investigated variants in the germline (n=19) with
over half (n=21) investigating intended effects and less than one-
quarter (n=7) adverse outcomes. For those genes exposed to
meta-analysis, the median number of studies per gene was 22
Figure 4. Categories of drugs evaluated in pharmacogenetic studies of the 10 most frequently studied genes. (a) pharmacodynamic;
and (b) pharmacokinetic. Numbers represent total studies per gene and drug category, with cell color shading to emphasize value (heat matrix).
CNS=central nervous system; ENT=ears, nose and throat. Drugs are classified as in British National Formulary (http://www.bnf.org).
doi:10.1371/journal.pone.0007960.g004
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category (85.7%) involved the 10 most frequently studied genes,
and 5 of 7 (71.4%) in the pharmacokinetic category. However,
only 4 of 15 (26.7%) meta-analyses in the pharmacodynamic
category involved the 10 most studied genes.
FDA-Supported Pharmacogenetic Tests
We next assessed the evidence-base for pharmacogenetic tests
listed by the FDA. At the time this study was performed (pre-July
09), the FDA had published guidelines on ‘‘valid genomic
biomarkers’’, [10] classifying pharmacogenetic tests into (i)
Figure 5. Sample size of pharmacogenetic studies from 1987 to 2007 (inclusive). Horizontal bars designate the median, boxes indicate 25
th
and 75
th centiles of the distribution and vertical bars represent the non-outlier range.
doi:10.1371/journal.pone.0007960.g005
Figure 6. Distribution of p values in 161 full-text primary research articles in pharmacogenetics.
doi:10.1371/journal.pone.0007960.g006
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2009, the website was updated [31] with removal of the classi-
fication system, however the list of ‘‘valid genomic biomarkers’’
and supporting references remained largely unchanged. We based
our analysis on the original guidelines with accompanying
classification system (Document S1).
Of the 136 references listed by the FDA in support of
pharmacogenetic testing, one article was indexed in Medline as a
meta-analysis (Figure 8), 63 (46%) were annotated either as clinical
trials/government-supported research or comparative studies, with
the remainder (48 studies, 35%) being reviews, case reports or
historical articles and 24 being unclassified. Only a small proportion
of the 1668 articles identified from our search mapped to relevant
FDA endorsed pharmacogenetic tests (n=101, Table S1). FDA
recommended or mandated pharmacogenetic tests were more likely
to investigate adverse effects, involve pharmacokinetic genes and
relate to cardiovascular disease (p=1.43610
216, 1.45610
27 and
5.06610
27 respectively).
Discussion
A distinctive feature of the field of pharmacogenetics is the
predominance of publications indexed as reviews, commentaries,
letters and other opinion based pieces over primary research
articles, whichever search strategy we used to identify articles. This
may have contributed to a high expectation of the delivery of
personalized medicines [5,6,7] with modest realisation of this goal
thus far. Though expanding in general, pharmacogenetic research
currently centres mainly in cancer, cardiovascular and neurolog-
ical/psychiatric disease with most studies being set in Europe and
North America, presumably mainly among subjects of European
ancestry. The relative dearth of research in other therapeutic areas
(e.g. communicable disease) and among individuals of non-
European ancestry, among whom there is a considerable global
disease burden, may be creating an imbalance that will require
addressing in future work. Even if the relevant genetic variants and
effect sizes are homogeneous across different ancestral groups [32],
differences in allele frequency can vary greatly [33] and such
variation means that the population impact of genetic variants
influencing drug response will often differ by ethnicity even if effect
sizes are similar.
The major goal of pharmacogenetic research is development of
genotype-based predictive tests of efficacy or toxicity. However, a
prerequisite is the reliable identification of the relevant genetic
loci. In genetic work, where many hundreds of thousands of
hypotheses can be tested, research designs are needed that
optimise the detection of true positive (while limiting the potential
for false positive) association [17,18,19]. Despite some high quality
studies, in broad terms, there are several features of the field as a
whole that suggest that only a proportion of the positive
associations reported are genuine. These include: the small size
of most studies coupled with the more frequent evaluation of
common rather than rare variants (whose effect sizes would be
predicted to be small and which therefore requires large sample
sizes for their reliable detection); use of surrogate (usually
continuous) outcome measures rather than more clinically relevant
binary outcomes; and subgroup analyses with multiple hypothesis
testing. Our study may have been limited by analysing only the
abstracts of articles satisfying inclusion criteria. However, detailed
data (information unlikely to be reported in abstracts) on outcome
measures (binary/continuous), gene variants and reported p values
were derived from the full text of a subset of 10%, which
accurately reflected the span of studies in the database.
Similar problems to those we highlight were recognised in the
field of genetics of common disease a decade or so ago. What
followed were efforts to systematically and comprehensively collate
evidence from genetic association studies, large collaborative meta-
analyses, larger primary studies, more comprehensive capture of
genetic variation at any given locus, independent replication, and,
most recently, whole genome association studies [26]. These
Figure 7. The theoretical number of total comparisons in 161 full-text articles. Calculated by multiplying the number of gene alleles
studied by the number of drugs investigated by the number of outcomes recorded.
doi:10.1371/journal.pone.0007960.g007
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genetic associations that are providing new insights into disease
pathogenesis, potential therapeutic targets and the possibility of
developing predictive tests for disease. Several important and
laudable efforts to collate and curate information on the genetic
basis of drug response already exist, including those of the
Pharmacogenetics Research Network [34]. However, the chal-
lenge in identifying primary pharmacogenetic studies is illustrated
by our two alternative search strategies. Our comprehensive
Medline search was sensitive (yielding .100,000 articles) but non-
specific, with a large number of evaluated articles not satisfying our
definition of a pharmacogenetic study. However, using a specific
search strategy (via the MeSH tool) the majority of articles were
missed. We know of no previous attempts to systematically identify
all published pharmacogenetic studies in this way but our current
analysis suggests that future attempts to do so should adopt an
explicit, systematic and comprehensive search strategy such as
the one we have used here. The terms ‘‘pharmacogenomic’’ and
‘‘pharmacogenetic’’ have both been used somewhat interchange-
ably in the literature. For example the Pharmacogenomics
Knowledge database (PharmGKB; http://www.pharmgkb.org/
resources/forGeneralUsers/pharmacogenetics_pharmacogenomics_
and_personalized_medicine.jsp accessed 2009 November 10, ar-
chived URL http://www.webcitation.org/5lBBtDJPf) defines phar-
macogenetics as ‘‘the study of … varying responses to drugs and the
determination of the genetic mutations underlying these variations’’
and pharmacogenomics as ‘‘the study of drug response in the context
of the entire genome’’. However, the Human Genome Project
information portal (http://www.ornl.gov/sci/techresources/Human_
Genome/medicine/pharma.shtml#whatis accessed 2009 November
10, archived URL http://www.webcitation.org/5lBCB8i5T) defines
pharmacogenomics as ‘‘the study of how an individual’s genetic
Table 2. Summary of meta-analyses of pharmacogenetic studies.
Gene category
Gene or region (number of
meta-analyses if .1)
Total number of
individual studies
Median no of studies
per gene per category
Median sample size of meta-analyses
(IQR) per gene per category
Somatic (12 meta-analyses, 7 genes) 30 503 (230–756)
ABCB1 1 21
chr8 5
EGFR (4) 1 30
ERBB2 (2) 1 37
FLT3 1 11
RAS* 1 25
TP53 (2) 1 62
Dynamic (10 meta-analyses, 15 genes) 5 2,183 (751–6,638)
ACE 1 72
APOA* 5
APOE 1 87
CETP 10
ESR* 4
F2 5
F5 1 20
HLA* 7
HTR2A 15
HTR2C 5
ITPA 1
MKRN2 2
NQO2 1
SLC6A4 3
TNF 1 20
Kinetic (9 meta-analyses, 7 genes) 52 1,450 (161–3,029)
ABCB1 1 67
CYP* 2
CYP2C19 1 76
CYP2C9 (3) 1 52
CYP2D6 1 84
CYP3A4 1 23
CYP7A1 1
1In top 10 most frequently studied genes in relevant category.
*denotes more than one gene.
doi:10.1371/journal.pone.0007960.t002
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classifications are exemplified by the U.S. National Library of
Medicine’s ‘controlled vocabulary’ for indexing articles via MeSH
terminology: ‘‘pharmacogenomics’’ is not a MeSH term, on
entering it in Medline, all articles indexed with the MeSH term
‘‘pharmacogenetics’’ are displayed.
Other developments that may be helpful include: a greater use
of meta-analysis, particularly where four or more independent
studies of the same gene have been conducted, perhaps with an
online, continuously updated database similar to those established
for Alzheimer’s Disease, Parkinson’s Disease and Schizophrenia
[35,36,37,38]. Other improvements might include: primary
studies with larger sample sizes; wider use of haplotype tagging
single nucleotide polymorphisms (SNPs); studies of rare and
structural genetic variants whose effects are predicted to be larger,
and which may therefore be more suited for use as predictive tests;
and a greater focus on genes influencing drug handling and
adverse effects, to fill gaps in knowledge [39].
Important studies with some of these features have been
reported since the deadline we set for our literature search. For
example, the identification of a SNP in the SLCO1B1 gene,
encoding the organic anion-transporting polypeptide OATP1B1,
as a susceptibility factor for statin-induced myopathy involved a
genome-wide association analysis of 85 individuals with definite or
incipient statin myopathy (and 90 controls) from a trial involving
over 12,000 subjects [40]. Here, the small size of the genome-wide
association study belies the large-scale effort to identify the few
subjects who suffer extreme adverse effects. This study provides a
paradigm for the identification of genetic loci underlying rare but
serious adverse effects of a commonly used drug. Other examples
which could be studied in a similar way include heparin-induced
thrombocytopaenia (frequency 0.5–2%), oesteonecrosis of the jaw
from bisphosphonate treatment (prevalence 4–7% in those
receiving intravenous bisphosphonates for hypercalcaemia of
malignancy), and angio-oedema from angiotensin converting
enzyme inhibitors. Because of the large genetic effect sizes that
might be detected with this approach (for example an odds ratio of
17 for statin myopathy in SLCO1B1 CC homozygotes), predictive
tests may be more likely to emerge, though the rarity of the
adverse effect means that rigorous assessment of the cost-
effectiveness of the approach would first be required. Larger scale
candidate gene studies[41,42,43,44] are also providing much more
secure evidence on loci influencing both drug response and
adverse effects that might form the basis of predictive testing for
dose adjustment or avoidance of toxic treatments.
As more reliable information begins to emerge on alleles
influencing drug response from larger, better designed whole
genome and candidate gene studies, focus will need to shift to the
critical evaluation of the predictive performance of genetic tests in
clinical practice, including studies of cost-effectiveness. These
evaluations will require use of different metrics to those
conventionally reported in discovery-based genetic studies (such
as odds ratios or proportion of variance explained) [45,46,47].
Instead, sensitivity and specificity, predictive values and the
generation of multivariate models that include genotype will need
evaluating [42,48]. In some cases, the most robust evaluation of
the effectiveness of genetic tests may need to come from
randomised trials comparing health outcomes among people
randomised to pharmacogenetic testing or no testing, together
with cost-effectiveness analyses as are now common when
evaluating the usefulness of interventions. In concert, these efforts
should help realise the promise of personalised medicines with
resultant improvements in healthcare. Our recommendations for
pharmacogenetic research are summarised below.
Recommendations for Future Research in
Pharmacogenetics
Primary research in pharmacogenetics should:
N give due emphasis both to adverse as well as intended effects of
drugs
N be appropriately powered
N examine clinically-relevant end-points
N be conducted among individuals of non-European as well as
European ancestry
N include studies of currently neglected drugs and disease areas
N enhance the likelihood of identification of large effect sizes
necessary for the generation of usefully predictive tests through
the study of rare or structural genetic variants, and/or more
extreme phenotypic differences in response or toxicity
N ensure comprehensive SNP typing where candidate loci are
studied
N utilise whole genome analysis where mechanisms are uncertain
N avoid post-hoc subgroup analysis, except where justified and
powered, and report the findings with due caution
N include evidence of independent replication
N exploit existing large randomised controlled trial datasets as a
resource for pharmacogenetic evaluation (e.g. SLCO1B1
variants and statin-induced myopathy, based on the SEARCH
trial involving 12,064 participants) [40]
Mechanisms should exist for:
N encouraging reporting null findings from high-quality studies
Figure 8. Medline annotation of studies provided by U.S. Food
and Drug Administration (FDA; n=136) as references for
‘‘approved biomarkers.’’
doi:10.1371/journal.pone.0007960.g008
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disseminating reports of pharmacogenetic research, to high-
light continuing gaps in knowledge and promote successes
N encouraging high quality updated systematic reviews and
meta-analyses of pharmacogenetic research
Promising genotype-based predictive tests emerging from
primary research should be:
N re-evaluated in independent prospective studies
N assessed against clinically relevant outcomes
N evaluated using the appropriate metrics for diagnostic,
screening and predictive tests
N tested where appropriate in randomised trials
Supporting Information
Document S1 U.S. Food and Drug Administration (FDA) Table
of Valid Genomic Biomarkers in the Context of Approved Drug
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DOC)
Author Contributions
Conceived and designed the experiments: MVH AH JPC. Performed the
experiments: MVH TS CV AH JPC. Analyzed the data: MVH AH JPC.
Contributed reagents/materials/analysis tools: MVH TS LS AH JPC.
Wrote the paper: MVH LS AH JPC.
References
1. Connor S (2003) Glaxo chief: Our drugs do not work on most patients. The
Independent. Available: http://www.independent.co.uk/news/science/glaxo-
chief-our-drugs-do-not-work-on-most-patients-575942.html Accessed 2009 No-
vember 10, Archived URL: http://www.webcitation.org/5lBCqy0gg.
2. Pirmohamed M, James S, Meakin S, Green C, Scott AK, et al. (2004) Adverse
drug reactions as cause of admission to hospital: prospective analysis of 18 820
patients. BMJ 329: 15–19.
3. Hunter DJ, Altshuler D, Rader DJ (2008) From Darwin’s finches to canaries in
the coal mine–mining the genome for new biology. N Engl J Med 358:
2760–2763.
4. Lemonick MD, Cray D, Park A, Thomas CB, Thompson D (2001) Brave New
Pharmacy. Time. Available: http://www.time.com/time/magazine/article/
0,9171,998963-1,00.html Accessed 2009 November 10, Archived URL:
http://www.webcitation.org/5lBD8FmTx.
5. Marr K (2008) A Glimpse Into Personalized Medicine of the Future. The
Washington Post. Available: http://www.washingtonpost.com/wp-dyn/content/
article/2008/09/28/AR2008092802482.html Accessed 2009 November 10,
Archived URL: http://www.webcitation.org/5lBDFAeE7.
6. Pollack A (November 8, 2005) A Special Drug Just for You, At the End of a
Long Pipeline. The New York Times. Available: http://www.nytimes.com/
2005/11/08/health/08phar.html Accessed 2009 November 10, Archived URL:
http://www.webcitation.org/5lBVt5O2X.
7. Roses AD (2000) Pharmacogenetics and the practice of medicine. Nature 405:
857–865.
8. Goldstein DB (2009) Common genetic variation and human traits. N Engl J Med
360: 1696–1698.
9. Goldstein DB, Tate SK, Sisodiya SM (2003) Pharmacogenetics goes genomic.
Nat Rev Genet 4: 937–947.
10. (2006) Table of Valid Genomic Biomarkers in the Context of Approved Drug
Labels. FDA (Created 2006 September 15, Updated 2008 September 10,
Removed 2009 June). Accessed 2009 January 12, Archived URL: http://www.
webcitation.org/5l6cpblur (older version). See Document S1 (recent version
prior to removal of website).
11. McClain MR, Palomaki GE, Piper M, Haddow JE (2008) A rapid-ACCE review
of CYP2C9 and VKORC1 alleles testing to inform warfarin dosing in adults at
elevated risk for thrombotic events to avoid serious bleeding. Genet Med 10:
89–98.
12. Hynicka LM, Cahoon WD Jr, Bukaveckas BL (2008) Genetic testing for
warfarin therapy initiation. Ann Pharmacother 42: 1298–1303.
13. Shurin SB, Nabel EG (2008) Pharmacogenomics–ready for prime time?
N Engl J Med 358: 1061–1063.
14. Ioannidis JP, Ntzani EE, Trikalinos TA, Contopoulos-Ioannidis DG (2001)
Replication validity of genetic association studies. Nat Genet 29: 306–309.
15. Ioannidis JP, Trikalinos TA, Ntzani EE, Contopoulos-Ioannidis DG (2003)
Genetic associations in large versus small studies: an empirical assessment.
Lancet 361: 567–571.
16. Colhoun HM, McKeigue PM, Davey Smith G (2003) Problems of reporting
genetic associations with complex outcomes. Lancet 361: 865–872.
17. Ioannidis JP, Gwinn M, Little J, Higgins JP, Bernstein JL, et al. (2006) A road
map for efficient and reliable human genome epidemiology. Nat Genet 38: 3–5.
18. Higgins JP, Little J, Ioannidis JP, Bray MS, Manolio TA, et al. (2007) Turning
the pump handle: evolving methods for integrating the evidence on gene-disease
association. Am J Epidemiol 166: 863–866.
19. Ioannidis JP, Boffetta P, Little J, O’Brien TR, Uitterlinden AG, et al. (2008)
Assessment of cumulative evidence on genetic associations: interim guidelines.
Int J Epidemiol 37: 120–132.
20. Pennisi E (2007) Breakthrough of the year. Human genetic variation. Science
318: 1842–1843.
21. Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for
systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6:
e1000097.
22. Ioannidis JP (2005) Why most published research findings are false. PLoS Med
2: e124.
23. Ioannidis JP (2008) Effect of formal statistical significance on the credibility
of observational associations. Am J Epidemiol 168: 374–383; discussion
384–390.
24. Ioannidis JP, Trikalinos TA, Khoury MJ (2006) Implications of small effect sizes
of individual genetic variants on the design and interpretation of genetic
association studies of complex diseases. Am J Epidemiol 164: 609–614.
25. Bodmer W, Bonilla C (2008) Common and rare variants in multifactorial
susceptibility to common diseases. Nat Genet 40: 695–701.
26. Hindorff LA JH, Mehta JP, Manolio TA (2009) A catalog of published genome-
wide association studies. National Human Genome Research Institute.
Available: www.genome.gov/26525384 Accessed 2009 November 10, Archived
URL: http://www.webcitation.org/5lBRp4wFx.
27. Khoury MJ, Little J, Gwinn M, Ioannidis JP (2007) On the synthesis and
interpretation of consistent but weak gene-disease associations in the era of
genome-wide association studies. Int J Epidemiol 36: 439–445.
28. Altshuler D, Hirschhorn JN, Klannemark M, Lindgren CM, Vohl MC, et al.
(2000) The common PPARgamma Pro12Ala polymorphism is associated with
decreased risk of type 2 diabetes. Nat Genet 26: 76–80.
29. Frank B, Wiestler M, Kropp S, Hemminki K, Spurdle AB, et al. (2008)
Association of a common AKAP9 variant with breast cancer risk: a collaborative
analysis. J Natl Cancer Inst 100: 437–442.
30. Sagoo GS, Tatt I, Salanti G, Butterworth AS, Sarwar N, et al. (2008) Seven
lipoprotein lipase gene polymorphisms, lipid fractions, and coronary disease: a
HuGE association review and meta-analysis. Am J Epidemiol 168: 1233–1246.
31. (2009) Table of Valid Genomic Biomarkers in the Context of Approved Drug
Labels (Updated 2009 July 8 and 2009 August 18). FDA. Available: http://
www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/
ucm083378.htm Accessed 2009 November 7, Archived URL: http://www.
webcitation.org/5l6d2Q4LH.
32. Ioannidis JP, Ntzani EE, Trikalinos TA (2004) ‘Racial’ differences in genetic
effects for complex diseases. Nat Genet 36: 1312–1318.
33. Limdi NA, Arnett DK, Goldstein JA, Beasley TM, McGwin G, et al. (2008)
Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation
attainment and maintenance among European-Americans and African-Amer-
icans. Pharmacogenomics 9: 511–526.
34. Pharmacogenetics Research Network. National Institute of General Medical
Sciences, NIH. Available: http://www.nigms.nih.gov/Initiatives/PGRN Ac-
cessed 2009 November 10, Archived URL: http://www.webcitation.org/
5lBSkNtMF.
35. SchizophreniaGene (SZGene), Schizophrenia Research Forum. Available:
http://www.schizophreniaforum.org/res/sczgene Accessed 2009 November
10, Archived URL: http://www.webcitation.org/5lBSs9qHy.
36. Bertram L, McQueen MB, Mullin K, Blacker D, Tanzi RE (2007) Systematic
meta-analyses of Alzheimer disease genetic association studies: the AlzGene
database. Nat Genet 39: 17–23.
37. Frodsham AJ, Higgins JP (2007) Online genetic databases informing human
genome epidemiology. BMC Med Res Methodol 7: 31.
38. Tang S, Zhang Z, Kavitha G, Tan EK, Ng SK (2009) MDPD: an integrated
genetic information resource for Parkinson’s disease. Nucleic Acids Res 37:
D858–862.
39. Woodcock J, Lesko LJ (2009) Pharmacogenetics–tailoring treatment for the
outliers. N Engl J Med 360: 811–813.
Pharmacogenetic Field Synopsis
PLoS ONE | www.plosone.org 13 December 2009 | Volume 4 | Issue 12 | e796040. Link E, Parish S, Armitage J, Bowman L, Heath S, et al. (2008) SLCO1B1
variants and statin-induced myopathy–a genomewide study. N Engl J Med 359:
789–799.
41. Colombo S, Rauch A, Rotger M, Fellay J, Martinez R, et al. (2008) The HCP5
single-nucleotide polymorphism: a simple screening tool for prediction of
hypersensitivity reaction to abacavir. J Infect Dis 198: 864–867.
42. Klein TE, Altman RB, Eriksson N, Gage BF, Kimmel SE, et al. (2009)
Estimation of the warfarin dose with clinical and pharmacogenetic data.
N Engl J Med 360: 753–764.
43. Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, et al. (2009) Cytochrome
p-450 polymorphisms and response to clopidogrel. N Engl J Med 360: 354–362.
44. Simon T, Verstuyft C, Mary-Krause M, Quteineh L, Drouet E, et al. (2009)
Genetic determinants of response to clopidogrel and cardiovascular events.
N Engl J Med 360: 363–375.
45. Jakobsdottir J, Gorin MB, Conley YP, Ferrell RE, Weeks DE (2009)
Interpretation of genetic association studies: markers with replicated highly
significant odds ratios may be poor classifiers. PLoS Genet 5: e1000337.
46. Janssens AC, Aulchenko YS, Elefante S, Borsboom GJ, Steyerberg EW, et al.
(2006) Predictive testing for complex diseases using multiple genes: fact or
fiction? Genet Med 8: 395–400.
47. Kraft P, Wacholder S, Cornelis MC, Hu FB, Hayes RB, et al. (2009) Beyond
odds ratios - communicating disease risk based on genetic profiles. Nat Rev
Genet.
48. Bromley CM, Close S, Cohen N, Favis R, Fijal B, et al. (2009) Designing
pharmacogenetic projects in industry: practical design perspectives from the
Industry Pharmacogenomics Working Group. Pharmacogenomics J 9: 14–22.
Pharmacogenetic Field Synopsis
PLoS ONE | www.plosone.org 14 December 2009 | Volume 4 | Issue 12 | e7960